new Risk Evaluation and Mitigation Strategy (REMS) to reduce the misuse of long-acting opioids
FDA will encourage you to participate in a new Risk Evaluation and Mitigation Strategy (REMS) to reduce the misuse of long-acting opioids.
Unintentional deaths due to opioids have quadrupled in 8 years...and treatment for opioid abuse has increased five-fold in 10 years.
Now FDA will require manufacturers to come up with a REMS plan by mid-August...with the changes rolled out by early 2012.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote